Nirav Shah

47PUBLICATIONS
208CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Hybrid and electric vehicles and powertrainsHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (47)

|Jul 28, 2026
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

|Jun 22, 2026
Itacitinib plus calcineurin inhibitor-based therapy for prophylaxis of graft-versus-host disease: GRAVITAS-119 results.

|Jun 12, 2026
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

|Mar 19, 2026
Everybody gets a CAR! But do they need it?

Nirav N Shah

|Feb 03, 2026
Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Lyndsey Runaas, Salena Fank, Katie Palen

|Jan 16, 2026
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Krish Patel, Julie M Vose, Sunita D Nasta

Pageof 8

Frequent Collaborators

12 joint publications

Mehdi Hamadani

9 joint publications

Shuo Ma

8 joint publications

Narendranath Epperla

6 joint publications

Chan Y Cheah